It works by imitating the natural GLP-1 hormone, which regulates appetite and digestion
The scientific literature confirms this pattern
Wegovy is a GLP-1 agonist that stimulates insulin release and is intended for long-term use
Appetite suppression reverses within 2 to 4 weeks after discontinuing semaglutide as the compound clears your system
however, it had no significant effect on MELD-Na score, international normalized ratio, total serum bilirubin, albumin level, or Child-Pugh score (NCT03205345)
Novo Nordisk said it is not currently conducting any clinical studies to evaluate semaglutide in patients with substance-use disorders or addiction-related illnesses, although changes in alcohol consumption is a secondary goal of a trial it is conducting of semaglutide in combination with other medicines in patients with alcohol-related liver disease